Walgreens Boots Alliance focuses on U.S. pharmacy footprint, shares trade in a weak retail peer group

Walgreens Boots Alliance opens the week with investors watching its U.S. pharmacy turnaround while the shares lag large-cap peers like CVS and Walmart. Consensus expectations and sector positioning frame the picture for the NYSE-listed stock.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 13:34.

Walgreens Boots Alliance (US9314271019) remains a core U.S. pharmacy chain on the NYSE, with investors focused on its ability to stabilize earnings after several challenging quarters. Against a broad U.S. retail universe including CVS Health and Walmart, the shares trade with a cautious sentiment according to recent analyst commentary.

What recent commentary highlights

Sell-side coverage in June continues to describe Walgreens Boots Alliance as a restructuring story, with a material earnings contribution still coming from its brick-and-mortar pharmacy network in the United States and the Boots franchise in the United Kingdom, according to multiple Wall Street notes. MarketWatch analyst overview for Walgreens Boots Alliance Several houses keep Neutral or equivalent ratings in place, often citing execution risk around cost savings and healthcare-services expansion.

Compared with CVS Health and Walmart, both of which have broader diversification into insurance, primary care or big-box retail, Walgreens Boots Alliance is seen more concentrated in prescriptions and front-of-store retail categories, which leaves earnings more exposed to volume and reimbursement trends, according to recent sector comparisons from U.S. broker research. Reuters sector analysis on U.S. drugstore chains

Analyst consensus and expectations

Consensus data compiled by several financial platforms still point to a mixed recommendation profile for Walgreens Boots Alliance, with a blend of Buy, Hold and Sell ratings, reflecting divided views on the pace and sustainability of the turnaround strategy. TipRanks consensus summary for WBA Price targets cluster around levels that imply limited upside from recent trading ranges, consistent with a cautious stance.

For the current fiscal year, analysts expect Walgreens Boots Alliance to continue prioritizing free cash flow generation and debt reduction, alongside selective investments in healthcare partnerships and digital pharmacy capabilities, as highlighted in recent earnings recaps and preview notes from U.S. brokerages. Barron’s roundup of research ratings for Walgreens Boots Alliance Many models still build in modest margin pressure from reimbursement dynamics and wage inflation, partly offset by cost-cutting measures.

The business behind the stock

Walgreens Boots Alliance generates most of its revenue through its Walgreens retail pharmacy chain in the United States and the Boots pharmacy and beauty stores in the United Kingdom, complemented by wholesale and healthcare services businesses that supply medicines and health products to pharmacies, hospitals and other providers.

Where the shares trade today

The Walgreens Boots Alliance shares (US9314271019) trade on the NYSE in U.S. dollars; the latest verifiable quote on a major financial data platform shows the stock changing hands around the mid-teens dollar range during recent sessions, with intraday updates available via U.S. exchange feeds.

Key data on the Walgreens Boots Alliance shares

• Company: Walgreens Boots Alliance, Inc.
• ISIN: US9314271019
• WKN: A12HJF
• Ticker: WBA
• Trading venue: NYSE
• Price (as of 2026-06-22, 21:59): 15.80 USD
• Market cap: 13.6 billion USD (as of 2026-06-22)
• Sector / industry: Consumer Staples / Drug Retail
• Index membership: NASDAQ-100, S&P 500
• Next earnings date: 2026-06-27

This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any financial instrument. Investors should conduct their own research or consult a qualified advisor before making investment decisions.